Cyclo Therapeutics to Present at SSIEM Annual Symposium 2024

Cyclo Therapeutics, Inc., a clinical-stage biotechnology firm listed on Nasdaq under the ticker CYTH, revealed that two of its abstracts have been approved for poster presentations at the upcoming SSIEM Annual Symposium 2024, scheduled from September 3-6 in Porto, Portugal. Cyclo Therapeutics is dedicated to the development of transformative medicines for patients and families affected by various diseases.

N. Scott Fine, the Chief Executive Officer of Cyclo Therapeutics, expressed his excitement about presenting their research at this significant scientific gathering. Fine emphasized the importance of their TransportNPC™ study, which is the most comprehensive ongoing controlled pivotal study focusing on Niemann-Pick Disease Type C1 (NPC1). According to Fine, the study stands out in terms of patient size, global reach, duration, and clinical outcomes. He noted the team's pride in the progress of the fully enrolled TransportNPC™ study and their strong belief in its potential impact on the NPC community worldwide.

The details of the poster presentations are as follows:

The first poster titled "TRANSPORTNPC™: Phase 3 global trial of intravenous hydroxypropyl-beta-cyclodextrin (HPβCD) in patients three years of age or older with Niemann-Pick disease type C1 (NPC1)" will be presented by a team comprising Caroline Hastings, Beata Kieć-Wilk, Lukasz Pawlinski, Faith Ezgu, Roberto Giugliani, Eugen Mengel, Elena Martin-Hernandez, Reena Sharma, Nicholas Smith, Nancy Chien, Sema Kalkan Ucar, Mark Walterfang, Victor Fung, Ozlem Goker-Alpan, Norberto Guelbert, Thorsten Marquardt, Leonardo Mendonça, Anna Ardissone, Alberto Burlina, Jordi Gascón, Loren Pena, Heidi Peters, Julian Raiman, Ronen Spiegel, Orna Staretz Chacham, Moeen AlSayed, Robin Lachmann, Dariusz Rokicki, Bryan Hurst, Bryan Murray, Andreas Brecht, and Joseph Mejia. Key discussion points for this poster include safety data, descriptive patient cohort data, and neurological outcomes using novel assessment technology.

The second poster is titled "TRANSPORTNPC™: Phase 3 global trial of intravenous hydroxypropyl-beta-cyclodextrin (HPβCD) in patients with Niemann-Pick disease type C1 (NPC1) – open label sub-study in patients below 3 years of age." It will be presented by Orna Staretz Chacham, Fatih Ezgu, Roberto Giugliani, Eugen Mengel, Sema Kalkan Ucar, Ronen Spiegel, Moeen AlSayed, Caroline Hastings, Bryan Hurst, Bryan Murray, Andreas Brecht, and Joseph Mejia. The key points of discussion for this poster will include safety data, clinical endpoints, and the concept of early intervention and prevention of disease progression.

About SSIEM, the Society for the Study of Inborn Errors of Metabolism (SSIEM), aims to foster the study of inherited metabolic disorders. The Society promotes the exchange of ideas among professionals from various disciplines interested in inborn errors of metabolism. This is facilitated through the organization of annual symposia and scientific meetings, publications, and funding for educational and training support. The SSIEM Council, supplemented by an Advisory Council, offers advice and meets during the annual symposium. The Society, a charity and limited company, accepts donations from supportive sponsors. Although it does not directly fund research, SSIEM provides advice to other organizations that do. Education and training in inborn errors of metabolism are also key objectives of SSIEM.

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company committed to developing life-changing medicines. Their product, Trappsol® Cyclo™, an orphan drug in the U.S. and Europe, is involved in four clinical trials for Niemann-Pick Disease Type C1, a rare genetic disease. The company is also conducting a Phase 2b trial for early Alzheimer's disease using Trappsol® Cyclo™. Additional indications for the active ingredient in Trappsol® Cyclo™ are under development.